Search

Search Constraints

You searched for: Author/Creator Berger, Adam

Search Results

1. 300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis. (10th December 2020)

2. 300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis. (9th November 2020)

3. 310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma. (9th November 2020)

4. 310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma. (9th November 2020)

5. 431 Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma. (9th November 2020)

6. 431 Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma. (9th November 2020)

7. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020)

8. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020)

9. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. (January 2019)

10. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. (October 2016)